Contract facts
FederalNo full NAICS 334516 intel page yet. Browse NAICS intelligence
ROCHE IMMUNO AUTOMATED CHEMISTRY, IMMUNOASSAY AND MOLECULAR TESTING PLATFORM AT USAFSAM EPIDEMIOLOGY LABORATORY - KITS, REAGENTS AND ASSAYS is a federal award for Fa2396 Usaf Afmc Afrl Pzl Afrl Pzle held by Roche Diagnostics Corp. Estimated value $327K ($327K obligated). Current period of performance ends Sep 15, 2022. Place of performance: DAYTON OH.
ROCHE IMMUNO AUTOMATED CHEMISTRY, IMMUNOASSAY AND MOLECULAR TESTING PLATFORM AT USAFSAM EPIDEMIOLOGY LABORATORY - KITS, REAGENTS AND ASSAYS
Recompete timing
PublicCurrent PoP ended Sep 15, 2022 (1436 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordRoche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract FA239622F0313?
FA239622F0313 (ROCHE IMMUNO automated chemistry immunoassay and) is a Fa2396 Usaf Afmc Afrl Pzl Afrl Pzle award with a potential value of $327K, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is FA2396-22-F-0313?
FA2396-22-F-0313 is the dashed form of PIID FA239622F0313 (ROCHE IMMUNO automated chemistry immunoassay and), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded FA239622F0313?
Fa2396 Usaf Afmc Afrl Pzl Afrl Pzle awarded FA239622F0313 to Roche Diagnostics Corp (potential $327K).
Who is the incumbent on FA239622F0313?
Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Sep 15, 2022.
When does Roche Diagnostics Corp’s FA239622F0313 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 15, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.